Review of the effects of anesthetic agents used as premedication for patients undergoing electroconvulsive therapy with diagnoses of bipolar disorder or major depression on convulsion, recovery period, and hemodynamic parameters by Ozen, Volkan & Orhan, Mehmet Emin
Journal of Mind and Medical Sciences
Volume 6 | Issue 2 Article 14
2019
Review of the effects of anesthetic agents used as
premedication for patients undergoing
electroconvulsive therapy with diagnoses of bipolar
disorder or major depression on convulsion,
recovery period, and hemodynamic parameters
Volkan Ozen
Mehmet Emin Orhan
Follow this and additional works at: https://scholar.valpo.edu/jmms
Part of the Anesthesiology Commons, Critical Care Commons, Mental and Social Health
Commons, and the Psychiatry Commons
This Research Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical
Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.
Recommended Citation
Ozen, Volkan and Orhan, Mehmet Emin (2019) "Review of the effects of anesthetic agents used as premedication for patients
undergoing electroconvulsive therapy with diagnoses of bipolar disorder or major depression on convulsion, recovery period, and




   
 
 
*Corresponding author: Volkan Ozen, Okmeydani Training and Research Hospital Kasimpasa Building, 
Department of Anesthesiology and Reanimation, 34440 Beyoğlu, İstanbul, Türkiye 





https://scholar.valpo.edu/jmms/   
https://proscholar.org/jmms/   
ISSN: 2392-7674 
J Mind Med Sci. 2019; 6(2): 271-277 
doi: 10.22543/7674.62.P271277 
 
Received for publication: March 20, 2019 
Accepted: May 16, 2019 
Research article 
Review of the effects of anesthetic agents 
used as premedication for patients 
undergoing electroconvulsive therapy with 
diagnoses of bipolar disorder or major 
depression on convulsion, recovery period, 
and hemodynamic parameters 
 Volkan Ozen1, Mehmet Emin Orhan2 
 
1Okmeydani Training and Research Hospital, Department of Anesthesiology and Reanimation, Istanbul,  
  Turkey  
2Gulhane Education and Research Hospital, Department of Anesthesiology and Reanimation, Ankara,  
  Turkey 
 
Abstract Objective: The aim of this study was to examine the effects of anesthetic agents used 
as premedication in patients undergoing electroconvulsive therapy (ECT) for diagnoses of 
bipolar disorder or major depression in terms of convulsion, recovery period, and 
hemodynamic parameters.  
Materials and Method: This retrospective study was carried out by screening the 
anesthesia forms of patients in a psychiatry clinic in Turkey.  
Results: Researchers reviewed 104 patient files, of which 39 fit the inclusion criteria. 
26 patients were given premedication; 13 patients were not given premedication. The study 
found a significant difference between the group to which dexmedetomidine was given 
and the non-premedication group in terms of mean arterial blood pressure and heart rate. 
A significant difference was also found between the group to which midazolam was given 
and the non-premedication group in terms of peripheral oxygen saturation.  
Conclusion: Premedication before ECT may be used to reduce the side effects after 
ECT without affecting convulsions and the recovery period. 
Keywords  convulsion, electroconvulsive therapy, hemodynamic, premedication, recovery 
Highlights ✓ Premedication should be administered before the electroconvulsive therapy 
✓ Premedication may prevent hemodynamic responses that may occur as a response to this 
therapy. It also prevents the occurrence of side effects. 
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Introduction 
Intravenous anesthetic agents such as short-acting 
midazolam and propofol are widely used to provide 
anesthesia in ECT applications (1). Ideal hypnotic 
medications used in ECT as anesthetics should have short 
half-lives, should not affect the onset/attack period and the 
quality, and should not disturb the hemodynamic balance. 
However, these anesthetic medications used for induction 
shorten the convulsion period and lengthen the recovery 
period, and also cause changes in hemodynamic 
parameters (2, 3).  
Constituting sufficient convulsion for an effective ECT 
enables the occurrence of the desired therapeutic effect. 
The motor attack period should continue for approximately 
20-30 seconds to achieve a successful clinical result. If the 
attack period is shorter than 15 seconds or longer than 120 
seconds, the ECT will be ineffective. One of the factors 
affecting this result is the anesthetic medication used. 
These medications may shorten the attack period by 
increasing the attack threshold based on the medication 
dose (2, 3). 
Although there have been no notifications about side 
effect occurrence in patients to whom ECT has been 
applied when dexmedetomidine and midazolam have been 
given, the number of studies examining these two sedative 
medications is low. A study by Mızrak et al. (4) indicated 
that low-dose dexmedetomidine given as premedication 
may be a beneficial alternative to midazolam. Several 
studies have reported that dexmedetomidine increases the 
attack period, while others have reported no effect on the 
attack period (5, 6). Various studies have shown that 
midazolam, which is an anticonvulsive agent in the 
benzodiazepine group and which decreases the 
hemodynamic response, prominently increases the attack 
period when used in ECT induction. However, studies that 
demonstrate an effect of midazolam applied in low doses 
as premedication on the attack period have been lacking (3, 
7).  
This study assessed the effects of anesthetic agents used 
as premedication for patients undergoing ECT for 
diagnoses of bipolar disorder or major depression in terms 
of convulsion, recovery period, and hemodynamic 
parameters.  
Materials and Methods 
This study was carried out at the psychiatry service of 
a training and research hospital by reviewing the files of 
patients to whom ECT was applied within a six-month 
period after the necessary approvals from the local ethical 
committee (Decision No: 2725, Meeting Date: June 6, 
2012) and from the institution were obtained. The 
researchers reviewed the follow-up forms of 18-65-year-
old patients who were categorized as physical status 1 and 
2 by the American Society of Anesthesiologists (ASA), 
who were diagnosed with bipolar disorder or major 
depression, and who underwent three sessions of ECT. 
Patients with ischemic heart disease, arrhythmia, 
hypertension, or epilepsy, or who were pregnant, used beta 
blockers, or were allergic to any medications, were not 
included in the study.  
The population considered for the study consisted of 
104 patients to whom ECT was given within a six-month 
period. Of these, 39 fit the inclusion criteria and thus were 
included. 26 patients had been given either 
dexmedetomidine (n = 13) or midazolam (n = 13), and no 
premedication occurred in another 13. In terms of 
premedication, 0.025 mg/kg IV midazolam or 0.5 μg/kg IV 
dexmedetomidine were administered by infusion. For the 
general anesthesia, a 4 mg/kg dose of thiopental and a 1 
mg/kg dose of succinylcholine were administered 
intravenously to all patients regardless of whether 
dexmedetomidine, midazolam, or no premedication had 
been previously administered.  
Researchers used a sub-structured questionnaire in 
which features related to descriptive characteristics, ECT 
side effects, and hemodynamic parameters of participants 
were recorded.  
o Questionnaire related to the descriptive 
characteristics of participants: This questionnaire 
included questions about the age, sex, height, weight, 
and the diagnosis of participants.   
o Questionnaire related to ECT side effects and 
hemodynamic parameters: Data for this 
questionnaire were obtained from patient files and were 
related to (1) the current amount given (in joules), (2) 
the mean arterial blood pressure (MAP), (3) heart rate 
(HR) and peripheral oxygen saturation (SpO2) values, 
(4) the recovery period, (4) the convulsion period, and 
(5) the side effects that occurred.   
Data were analyzed using the Statistical Package for 
Social Sciences (SPSS Inc., Chicago, IL., USA) 15.0 
program. The mean ± standard deviation and frequency 
analysis were used for descriptive statistics. The Kruskal-
Wallis test was used for inter-group comparisons of 
continuous variables. Bonferroni corrections for Mann-
Whitney U tests were used for advanced binary 
comparisons. Significant p values were set at < 0.05.  
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Results 
Table 1 presents the descriptive characteristics of the 
participants.  
The study found that dexmedetomidine was used in 13 
patients in Group I, and midazolam was used in 13 patients 
in Group II as premedication, and no premedication was 
used in 13 patients in Group III.  
No statistically significant difference between the 
groups were found in terms of age, height, weight, sex, or 
disease diagnosis.  
 
Table 1. Comparison of the descriptive characteristics of the participants 
Features 
Group I 
(n = 13) 
Group II 
(n = 13) 
Group III 
(n = 13) 
p 
(Mean ± SD) /  
n (%) 
(Mean ± SD) /  
n (%) 
(Mean ± SD) /  
n (%) 
Age (year) 32.6 ± 5.6 31.0 ± 9.7 29.8 ± 8.9 0.792 
Body Height 
(cm) 
172 ± 7.2 171.3 ± 10.1 170.6 ± 10.4 0.978 
Body Weight 
(kg) 
75.4 ± 15.5 74.6 ± 12.1 71.8 ± 11.9 0.628 
Sex  
   Female 












   Depression 











Group I: Patients given dexmedetomidine premedication. Group II: Patients given midazolam premedication. 
Group III: Patients given no premedication. 
  
Table 2 presents group comparisons of hemodynamic 
parameters, convulsion, and recovery periods. A 
statistically significant difference was found between the 
5th, 10th, and 15th minute after ECT in terms of MAP; 
between the 5th and 10th minute after ECT in terms of HR; 
and at the 10th minute after the premedication was given 
in terms of SpO2 value. Further analysis found that the 
difference between MAP and HR occurs across Groups I 
and III (p < 0.017), and the difference in SpO2 occurs 
across Groups II and III (p = 0.008). No statistically 
significant difference was found between groups in terms 
of recovery and convulsion periods (p > 0.05). 
 









(Mean ± SD) 
p 
MAP (mmHg)  
T0 91.1 ± 8.3 95.3 ± 9.8 92.8 ± 10.3 0.621 
T1 85.0 ± 8.9 90.1 ± 8.0 90.0 ± 10.1 0.277 
T2 83.4 ± 7.2 87.5 ± 8.2 88.0 ± 8.5 0.293 
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T3 102 ± 17.7 102.9 ± 9.7 112.0 ± 10.7 0.045* 
T4 90.6 ± 9.8 98.5 ± 10.8 104.0 ± 11.0 0.018* 
T5 88.8 ± 8.6 96.3 ± 9.9 99.0 ± 9.7 0.031* 
HR (min) 
T0 80.9 ± 7.5 86.0 ± 10.1 84.0 ± 14.1 0.344 
T1 75.5 ± 11.0 85.6 ± 10.3 83.4 ± 12.9 0.092 
T2 73.0 ± 9.5 81.1 ± 11.4 82.3 ± 13.3 0.096 
T3 85.9 ± 11.2 98.6 ± 12.9 99.1 ± 11.8 0.019* 
T4 84.7 ± 10.4 95.1 ± 10.2 99.3 ± 9.4 0.004* 
T5 85.5 ± 9.8 94.3 ± 12.7 94.6 ± 10.9 0.058 
SpO2 (%) 
T0 97.4 ± 1.7 97.3 ± 0.7 97.8 ± 1.3 0.620 
T1 96.9 ± 1.5 96.3 ± 1.8 97.7 ± 1.5 0.093 
T2 96.8 ± 1.5 95.8 ± 1.5 97.6 ± 1.4 0.028* 
T3 95.6 ± 2.6 96.0 ± 2.3 96.8 ± 2.6 0.475 
T4 94.5 ± 1.3 94.6 ± 1.5 94.6 ± 1.8 0.932 
T5 94.6 ± 1.7 94.9 ± 1.4 94.6 ± 1.8 0.514 
Convulsion period 
(min) 
19.2 ± 9.5 18.7 ± 6.6 24.8 ± 11.1 0.288 
Recovery period (min) 14.4 ± 5.3 12.9 ± 8.1 10.8 ± 4.8 0.156 
Group I - Patients given dexmedetomidine, Group II – Patients given midazolam, Group III - Patients 
given no premedication, T0 – The time before the premedication was administered to the patient, T1 - The 
5th minute after the premedication was administered to the patient, T2 - The 10th minute after the 
premedication was administered to the patient, right before induction, T3 - The 5th minute after ECT, T4 
- The 10th minute after ECT, T5 - The 15th minute after ECT, MAP – Mean arterial pressure, HR – Heart 
rate, SpO2 - peripheral oxygen saturation 
*p<0.050 
 
Table 3 shows the side effects noticed in the patients. 
The patients in Groups I, II, and III showed two, three, and 
five side effects, respectively. The most frequent side 
effects were tearing in Groups I and II and coughing in 
Group III. 
 
Table 3. Side effects noticed in patients 
Side effect 




n (%) n (%) n (%) n (%) 
Tearing 2 (15.4) 6 (37.5) 5 (27.7) 13 (27.7) 
Coughing 1 (7.7) 2 (12.0) 9 (50.0) 12 (25.5) 
Premedication in electroconvulsive therapy 
 275 
Urinary incontinence - - 2 (11.1) 2 (4.3) 
Postictal delirium - - 1 (6.3) 1 (2.1) 
Shivering - - 1 (5.6) 1 (2.1) 
Sweating - - 1 (5.6) 1 (2.1) 
Total* 3 8 19 30 
*n was folded. 
Group I - Patients given dexmedetomidine, Group II - Patients given midazola, Group III - Patients given 
no premedication. 
 
   
Discussions 
This study found a statistically significant difference 
between the dexmedetomidine group and the no 
premedication group in terms of MAP and HR. The 
incidence of side effects in patients given no premedication 
was higher than that in patients given premedication. 
Dexmedetomidine is an α2-adrenergic agonist which 
can be used with other intravenous anesthetic medications 
in various surgical fields. The use of dexmedetomidine in 
ECT may decrease hemodynamic responses (8-10). 
Previous studies have shown that MAP and HR decreased 
in patients to whom ECT was administered (5, 11, 12). The 
results of the present study show similar results.  
Anesthetic agents used in ECT are desirable as they 
decrease the recovery period (13). The effect of 
dexmedetomidine and midazolam on the recovery period 
is controversial in the research literature. Some studies 
have found that dexmedetomidine and midazolam increase 
the recovery period (14); however, other studies have 
found that they have no effect on the recovery period (4, 
11). The present study found no significant difference in 
terms of the recovery period between patients to whom 
dexmedetomidine and midazolam were administered as 
premedication and patients to whom no premedication was 
administered. 
Although the therapeutic action of ECT is not fully 
understood, the attack period is one of the more significant 
indicators related to the efficacy of the therapy (15). The 
recommended convulsion period is 25 seconds for 
effective ECT. Recent studies have reported that the 
healing efficiency of convulsions that continue for less than 
15 seconds is decreased (5). A study by Mızrak et al. (4) 
found that the convulsion periods in patients to whom 
dexmedetomidine was administered were longer than those 
of patients who were administered either midazolam or no 
premedication. A study by Loimer et al. (16) reported that 
midazolam shortened the attack period. According to the 
above-mentioned study by Mızrak et al. (4), 
dexmedetomidine may increase the attack period by 
allowing better convulsion activity than midazolam. The 
results of this study found that the attack periods in 
dexmedetomidine patients were longer than in midazolam 
patients. However, this difference was not statistically 
significant. This non-significant difference may have 
resulted from the use of barbiturates, which are known to 
decrease the attack activity when used as the induction 
agents in ECT.  
A statistically significant difference was found between 
midazolam patients and non-premedication in terms of 
SpO2 value at the 10th minute after the premedication. 
This effect may have resulted from midazolam suppressing 
the respiration center by decreasing oxygen consumption 
and cerebral circulation, based on the medication dose (17). 
Although side effects such as coughing, headache, 
postictal delirium, bradycardia, or hypertension due either 
to ECT or to the anesthetic agents used were observed in 
patients in a previous study, most of the patients had good 
prognoses and recovered on their own (18). Decreasing 
possible side effects that may occur in patients, and waking 
patients up in a comfortable way, are the aims of 
premedication administered before ECT (19). Mızrak et al. 
(4) reported that 4 patients developed coughing, and 5 
developed headaches among dexmedetomidine patients. 2 
patients developed coughing and 6 developed headaches 
among midazolam patients (4).  In the present study, only 
coughing and tearing occurred as side effects in 
premedication patients. In contrast, coughing, tearing, 
urinary incontinence, sweating, shivering, and postictal 
delirium occurred as side effects in patients given no 
premedication.  
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Conclusions 
Midazolam or dexmedetomidine administered as 
premedication before ECT may prevent acute 
hemodynamic responses that may occur as a response to 
this therapy. Therefore, premedication administration may 
be beneficial in reducing the side effects that occur after 
ECT without affecting either the convulsion or the 
recovery periods. 
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